Adaptimmune Therapeutics PLC — Director's Dealing 2016

Jan 20, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2016-01-18

Reporting Person: Rawcliffe Adrian (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-18	Option to purchase Ordinary Shares	$1.2717	A	939948	Acquired	2026-01-18	Ordinary Shares (939948)	Direct

Footnotes

F1: The exercise price was converted from GBP0.89 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the business day prior to the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

F2: Exercisable as to 234,987 Ordinary Shares on January 18, 2017 and will be exercisable as to the remainder in monthly installments of 19,582 Ordinary Shares on the eighteenth of each month from February 18, 2017 through December 18, 2019, and in one installment of 19,591 Ordinary Shares on January 18, 2020.